Journal Mobile Options
Table of Contents
Vol. 124, No. 4, 2001
Issue release date: April 2001
Int Arch Allergy Immunol 2001;124:423–431
(DOI:10.1159/000053777)

Chemokines, Chemokine Receptors and Allergy

Kaplan A.P.
Division of Pulmonary Diseases and Central Case Medicine and Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, S.C., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Chemokines are a group of cytokines that are responsible for the influx of blood cells, including T and B lymphocytes, monocytes, neutrophils, eosinophils and basophils, in allergic and other inflammatory conditions. They function as G protein-coupled chemotactic factors which also activate the cells with which they interact. Certain chemokines function within the afferent arm of the immune system, in which antigen is processed and antibody formation initiated, and others are active within the effector pathways of cellular immunity and late-phase allergic reactions. Th2 lymphocytes, which are critical for allergy, employ the CC chemokine receptors CCR4 and CCR8 with the ligands thymus- and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and I-309, respectively. The chemokine receptor CCR3 and ligands monocyte chemoattractant protein (MCP)-3, MCP-4, regulated upon activation normal T cell expressed and secreted (RANTES) and eotaxins I and II are of particular relevance for the recruitment and activation of eosinophils. Th1 reactions depend upon interferon γ-induced CXC chemokines interferon- inducible protein (IP)-10, interferon-inducible T cell-α chemoattractant (iTAC) and monokine induced by interferon-γ (MiG), which bind to chemokine receptor CXCR3.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lindhout E, Vissers JLM, Figdor CG, Adema GJ: Chemokines and lymphocyte migration. Immunologist 1999;147:152.
  2. Luster AD: Chemokines – chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–445.
  3. Zaballos A, Gutienez J, Varona R, Ardavin C, Marquez G: Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for chemokine TECK. J Immunol 1999;162:5671–5675.

    External Resources

  4. Kellermann S-A, Hudak S, Oldham ER, Liu Y-J, McEvoy LM: The CC chemokine receptor-7 ligands 6C-kine and macrophage inflammatory protein 3β are potent chemoattractants for in vitro and in vivo-derived dendritic cells. J Immunol 1999;162:3854–3864.
  5. Saeki H, Moore AM, Brown MJ, Hwang ST: Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participation in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999;162:2472–2475.
  6. Yang D, Howard OM, Chen Q, Oppenheim JJ: Cutting edge: Immature dendritic cells generated from monocytes in the presence of TGF-β1 express functional C-C chemokine receptor 6. J Immunol 1999;163:1737–1741.

    External Resources

  7. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai R, Yoshie O: Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem 1998;273:7118–7122.
  8. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B: B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts β-lymphocytes via BLR1/CXCR5. J Exp Med 1988;187:655–660.

    External Resources

  9. Adema GJ, Hartgers F, Verstraten R, DeVries E, Marland G, Menon S, Foster JS, Xu Y, Nooyen P, McClanahan T, Bacon KB, Figdor CG: A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997;387:713–717.
  10. Struyf S, Proost P, Sozzani S, Mantovani A, Wuyts A, De Clercq E, Schols D, Van Damme J: Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 1998;161:2672–2675.
  11. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackey CR: The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746–754.
  12. Bonecchi R, Bienchi G, Bordignon PP, D’Ambrosio D, Lang R, Borsetti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129–134.
  13. Andrew DP, Ching M, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP, Elias CG: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998;161:5027–5038.

    External Resources

  14. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of Th2 polarization by the chemokine monocyte chemotactic protein-1. Nature 2000;404:407–411.
  15. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Grozzo R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A: CTAK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999;96:14470–14475.
  16. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soter D: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 2000;165:2943–2949.
  17. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher ED, Andrew DP, Agace WW: Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestine immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192:761–767.
  18. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA: T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267–280.
  19. Romagnani P, DePaulis A, Beltrame C, Annunziato F, Dente V, Maggi E, Romagnani S, Marone G: Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 1999;155:1195–1204.
  20. Papadopoulos EJ, Fitzhugh DJ, Tkaczyk C, Gilfillan AM, Sassetti C, Metcalfe DD, Hwang ST: Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol 2000;30:2355–2361.
  21. Van der Bruggen T, Kanters D, Tool ATJ, Raaijmakers JA, Lammers JW, Verhoeven AJ, Koenderman L: Cytokine-induced protein tyrosine phosphorylation is essential for cytokine priming of human eosinophils. J Allergy Clin Immunol 1998;101:103–109.
  22. Bischoff SC, de Weck AL, Dahinden CA: Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA 1990;87:6813–6817.
  23. Miyajima A, Mui ALF, Ogorochi T, Sakamaki K: Receptors for granulocyte/macrophage colony stimulating factor, interleukin 3, and interleukin 5. Blood 1993;82:1960–1974.
  24. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T: Analysis of the survival of mature human eosinophils: Interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542–2547.
  25. Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ, Kaplan AP: Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 1992;175:484–493.
  26. Alam R, Lett-Brown MA, Forsythe PA, Anderson-Walters DJ, Kenamore C, Kormos C, Grant JA: Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Clin Invest 1992;89:723–728.
  27. Bischoff SC, Krieger M, Bhunner T, Dahinden CA: Monocyte chemotactic protein 1 is a potent activator of human basophils. J Exp Med 1992;175:1271–1275.
  28. Alam R, Forsythe P, Stafford S, Heinrich J, Bravo R, Proost P, Van Damme J: Monocyte chemotactic protein 2, monocyte chemotactic protein 3, and fibroblast induced cytokine: Three new chemokines induce chemotaxis and activation of basophils. J Immunol 1994;153:3155–3159.
  29. Dahinden CA, Geiser T, Brunner T, Von Tscharner V, Caput D, Ferrara P, Minty A, Baggiolini M: Monocyte chemotactic protein 3 is a most effective basophil and eosinophil-activating chemokine. J Exp Med 1994;179:751–756.
  30. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP: RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992;149:636–642.

    External Resources

  31. Alam R, Forsythe PA, Stafford S, Lett-Brown MA, Grant JA: Macrophage inflammatory protein-1α activates basophils and mast cells. J Exp Med 1992;176:781–786.

    External Resources

  32. Stellato C, Collins P, Ponath PD, Soler D, Newman W, LaRosa G, Li H, White J, Schwiebert LM, Bickel C, Liu M, Bochner BS, Williams T, Schleimer RP: Production of the C-C chemokine MCP 4 by airway cells and comparison of its biological activity to other C-C chemokines. J Clin Invest 1997;99:926–936.
  33. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Sadick M, Kaplan AP: Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol 1993;150:1932–1943.
  34. Rothenberg ME, Luster AD, Leder P: Murine eotaxins: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA 1995;42:8960–8964.
  35. Donath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo J-A, Newman W, Gutierrez-Ramos J-C, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin: Expression, receptor binding, and functional properties suggest a mechanism for the selective accumulation of eosinophils. J Clin Invest 1996;97:604–612.
  36. Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, Thelan M, Baggiolini M: Eotaxin-2, a novel C-C chemokine that is selective for the chemokine receptor CCR3 and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171–2176.
  37. Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Saito A, Takeda T, Imabeppu S, Kato Y, Hanai N, Anazawa H, Kuga T, Nishi T: A novel human C-C chemokine eotaxin-3, which is expressed in IL-4 stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999;163:1602–1610.
  38. Alam R, Stafford S, Forsythe P, Grant JA: RANTES is a chemotactic and activating factor for eosinophils. J Immunol 1993;150:3442–3448.
  39. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA: RANTES and macrophage inflammatory protein 1α induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489–1495.
  40. Shahabuddin S, Penoth P, Schleimer RP: Migration of eosinophils across endothelial cell monolayers: Interactions among IL-5, endothelial-activating cytokines, and C-C chemokines. J Immunol 2000;164:3847–3854.
  41. Kita H, Gleich GJ: Chemokines active in eosinophils: Potential roles in allergic inflammation. J Exp Med 1996;183:2421–2426.

    External Resources

  42. Palframan RT, Collins PD, Williams TJ, Rankin SM: Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91:2240–2248.
  43. Horie S, Gleich GJ, Kita H: Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol 1996;98:371–381.
  44. Center DM, Cruikshank WN: Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 1982;128:2563–2568.
  45. Kita H, Gleich EJ: The eosinophil: Structure and function; in Kaplan AP (ed): Allergy, ed 2. Philadelphia, W.B. Saunders, 1997, pp 148–178.
  46. Kuna P, Lazarovich M, Kaplan AP: Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:104–112.

    External Resources

  47. Humbles AA, Conroy DM, Marleau S, Rankin SM, Palframan RT, Proudfoot AEI, Wells TNC, Li D, Jeffrey PK, Griffiths-Johnson DA, Williams TJ, Jose PJ: Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: Analysis in a guinea pig model in vivo. J Exp Med 1997;186:601–612.
  48. Ying S, Robinson DS, Meng G, Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163:3976–3984.
  49. Taha RA, Minshell EM, Miotto D, Shimbara A, Luster A, Hagg JC, Hamid Q: Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatics and nonasthmatic individuals. J Allergy Clin Immunol 1999;103:476–483.
  50. Lilly CM, Woodruff PG, Camargo CA, Nakamura H, Drazen JM, Nadel ES, Hanrahan JP: Elevated plasma eotaxin levels in patients with acute asthma. J Allergy Clin Immunol 1999;104:786–780.
  51. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, Rothenberg MD, Luster AD, Hamid Q: Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593–4601.
  52. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schröder J-M: Eosinophil recruitment following antigen challenges is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol 1996;157:1806–1812.
  53. Lamkhioued B, Garcia-Zepeda EA, Abi-Younos S, Nakamura H, Jedrzkiewicz S, Wagner L, Renzi PM, Allakhverdi Z, Lilly C, Hemid Q, Luster AD: Monocyte chemoattractant protein (MCP)-4 expression in the airways of patients with asthma. Induction in epithelial cells and mononuclear cells by proinflammatory cytokines. Am J Respir Crit Care Med 2000;162:723–732.
  54. Alam R, York J, Boyars M, Stafford S, Grant JA, Lee J, Forsythe P, Sim T, Ida N: Increased MCP-1, RANTES, and MIP-1α in bronchoalveolar lavage fluid of allergic asthmatic patients. Am J Respir Crit Care Med 1996;153:1398–1404.
  55. Cieslewicz G, Tonkinson A, Adler A, Duez C, Schwarze J, Takeda K, Larson KA, Lee JJ, Irvin CG, Gelfand EW: The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest 1999;140:301–308.
  56. Kwon GJ, Jose PJ, Robbins RA, Schall TJ, Williams TJ, Barnes PJ: Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am J Respir Cell Mol Biol 1995;12:488–496.
  57. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen F-E: Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999;163:1545–1551.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50